Platelet activation and lipid peroxidation in patients with acute ischemic stroke

Stroke. 1997 Aug;28(8):1557-63. doi: 10.1161/01.str.28.8.1557.

Abstract

Background and purpose: Both platelet activation and lipid peroxidation are potential sources of vasoactive eicosanoids that can be produced via the cyclooxygenase pathway, ie, thromboxane (TX) A2, or by free radical-catalyzed peroxidation of arachidonic acid, ie, isoprostanes. We investigated the biosynthesis of TXA2 and F2-isoprostanes, as reflected by the urinary excretion of 11-dehydro-TXB2 and 8-epi-prostaglandin (PG) F2 alpha respectively, in 62 consecutive patients (30 men, 32 women; mean age, 67 +/- 14 years) with acute ischemic stroke.

Methods: At least two consecutive 6-hour urine samples were obtained during the first 72 hours after onset of symptoms. Urinary eicosanoids were measured by previously described radioimmunoassays.

Results: Repeated periods of enhanced thromboxane biosynthesis were found in 52% of patients. Urinary 11-dehydro-TXB2 averaged 221 +/- 207 (mean +/- SD; n = 197; range, 13 to 967) pmol/mmol creatinine in 30 patients treated with cyclooxygenase inhibitors (mostly aspirin) at the time of study versus 392 +/- 392 (n = 186; range, 26 to 2533) in 32 untreated patients (P < .001). The corresponding values for 8-epi-PGF2 alpha excretion were 74 +/- 42 (range, 14 to 206) and 83 +/- 65 (range, 24 to 570) pmol/mmol creatinine (P > .05). The correlation between the two metabolites was moderate in both untreated patients (r = .41, P < .001) and patients with cyclooxygenase inhibitors (r = .31, P < .001). In a multiple regression analysis, increased thromboxane production was independently associated with severity of stroke on admission, atrial fibrillation, and treatment with cyclooxygenase-inhibiting drugs.

Conclusions: We conclude that during the first few days after an acute ischemic stroke (1) platelet activation occurs repeatedly in a cyclooxygenase-dependent fashion; (2) platelet activation is not associated with concurrent changes in isoprostane biosynthesis; (3) platelet activation is independently associated with stroke severity and atrial fibrillation; and (4) isoprostane biosynthesis is largely independent of platelet cyclooxygenase activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Aged
  • Atrial Fibrillation / blood
  • Atrial Fibrillation / metabolism
  • Atrial Fibrillation / urine
  • Brain Ischemia / blood*
  • Brain Ischemia / metabolism*
  • Brain Ischemia / urine
  • Cerebrovascular Disorders / blood*
  • Cerebrovascular Disorders / metabolism*
  • Cerebrovascular Disorders / urine
  • Cyclooxygenase Inhibitors / therapeutic use
  • Dinoprost / urine
  • Female
  • Humans
  • Lipid Peroxides / metabolism*
  • Male
  • Middle Aged
  • Platelet Activation*
  • Reference Values
  • Thromboxane B2 / analogs & derivatives
  • Thromboxane B2 / urine

Substances

  • Cyclooxygenase Inhibitors
  • Lipid Peroxides
  • Thromboxane B2
  • 11-dehydro-thromboxane B2
  • Dinoprost